HD Medical Awarded FDA Clearance For HD Steth
14.7.2020 15:05:00 EEST | Business Wire | Press release
HD Medical, Inc. of Silicon Valley today announces that its flagship product, HD Steth, has received FDA clearance for all three product classification codes of DQD, DQC and DPS for Electronic Stethoscope, Phonocardiograph and Electrocardiograph combined into one device. HD Steth utilizes cutting-edge AI technology to enable clinicians to perform advanced cardiac evaluation at the point-of-care to save time and lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005235/en/
HD Steth and HD Steth App (Photo: Business Wire)
About HD Steth
HD Steth is an intelligent stethoscope that assists clinicians with capturing, recording, replaying and simultaneously visualizing heart sounds and ECG waveforms on a smart device to help detect multiple cardiac abnormalities. Patented visualization and noise cancellation technology gives HD Steth its edge. Subtle heart sounds are difficult or impossible to hear during auscultation. HD Steth delivers unsurpassed sound fidelity enhanced by visualization which allows clinicians to see the heart sounds providing instant cardiac insights.
Clinical Studies & International Sales Success
“The quality and intensity of heart sounds are phenomenal on HD Steth and it delivers the most impressive sound quality advancements in my last 40 years of stethoscope use,” said Dr. Ethiraj Raj, specializing in Cardiovascular Disease in Flint, Michigan. “The opportunity to amplify the sounds along with simultaneous visualization of heart sounds and ECG in real-time is unique. Physicians, teachers and medical students will greatly benefit from this revolutionary experience which will be a paradigm shift in cardiac auscultation. Congratulations to the HD Medical team for combining all these sensors that resulted in this exceptional instrument which will benefit the patient population as well as providers for years to come. It is truly a giant leap forward in technology.”
“HD Steth is the only stethoscope with four powerful microprocessors built into the device for advanced signal processing and intelligence, while still retaining the convenient form factor of a stethoscope,” said Shailendra Mahajan, board observer and managing director of Maxim Ventures, a major investor in HD Medical. “Components and sensors by Maxim Integrated Products, Inc. (NASDAQ: MXIM) enable low power consumption and better accuracy. The combination results in significant advantages over other products in the market.”
“Over the past year, HD Medical has been conducting multiple screening studies of over 50,000 children using HD Steth in India and has resulted in saving many lives. HD Medical has been selling internationally to medical professionals and institutions as well as domestically to veterinarians with great success. HD Medical can now market HD Steth in the U.S. and in other FDA-predicated global markets,” said Arvind Thiagarajan, founder & CEO of HD Medical. “The most intelligent stethoscope has been FDA cleared at this critically important time. During this challenging COVID-19 pandemic, HD Steth will significantly assist frontline health workers at the point-of-care detecting abnormal heart and lung sounds," he continues, welcoming the medical community to High-Fidelity Digital “HD” sound and instant visualization.
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299) for Product Classification Codes: DQD, DQC, DPS. The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions as well as veterinarians through channel partners. For more information please visit www.hdmedicalgroup.com.
Note to editors: HD Steth and HD Medical are registered trademarks of HD Medical, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005235/en/
Contact information
Kristi Furrer
HD Medical, Inc.
303.525.0924
kristi@hdmedicalgroup.com
info@hdmedicalgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 10:00:00 EEST | Press release
Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the DACH region,” said Sergio Liscia, Vice President Legal Software at Wolters Kluwer. “What makes this recognition particularly meaningful is that it reflects the experience of legal professionals themselves. Achieving the highest ratings for custom
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 09:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260719172592/en/ IQM's whitepaper on hybrid quantum optimization for railway scheduling, developed with Deutsche Bahn. Using a real operational dataset from Deutsche Bahn, a schedule of 190 trips across five German cities translating into roughly 98,500 possible cycles, the two organizations developed and tested a hybrid quantum-classical algorithm designed for enterprise-scale optimization problems. As detailed in a published whitepaper here, the IQM team applied the Quantum Approximate Optimization Algorithm (QAOA) in manageable stages, with the quantum component solving smaller subproblems within a classic
Galderma Launches Alastin ® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.1,2 This is increasing demand for integrated skincare solutions that support skin readiness, recovery and long-term quality.3,4,5 Alastin addresses this need through its range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom